Piper Jaffray Companies restated their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a report issued on Monday morning, TipRanks reports. They currently have a $104.00 price objective on the stock.
Other research analysts have also issued research reports about the company. Zacks Investment Research lowered Crispr Therapeutics from a hold rating to a sell rating in a report on Monday, September 30th. TheStreet upgraded Crispr Therapeutics from a d rating to a c rating in a report on Monday, October 28th. Chardan Capital reiterated a buy rating and set a $72.50 price target on shares of Crispr Therapeutics in a report on Monday, November 18th. BidaskClub lowered shares of Crispr Therapeutics from a strong-buy rating to a buy rating in a report on Friday. Finally, Wells Fargo & Co restated a buy rating on shares of Crispr Therapeutics in a report on Friday, December 6th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have given a buy rating to the stock. Crispr Therapeutics presently has an average rating of Buy and a consensus price target of $69.54.
NASDAQ CRSP opened at $66.33 on Monday. Crispr Therapeutics has a 52 week low of $22.22 and a 52 week high of $74.00. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The business’s fifty day simple moving average is $60.48 and its 200-day simple moving average is $48.87.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The business had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. As a group, sell-side analysts forecast that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.
In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at $412,500. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 56,118 shares of company stock worth $3,620,760. 21.40% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CRSP. BNP Paribas Arbitrage SA acquired a new position in Crispr Therapeutics in the 2nd quarter valued at about $41,000. Aperio Group LLC acquired a new position in Crispr Therapeutics in the 2nd quarter valued at about $153,000. Swiss National Bank grew its position in Crispr Therapeutics by 28.6% in the 2nd quarter. Swiss National Bank now owns 48,600 shares of the company’s stock valued at $2,289,000 after acquiring an additional 10,800 shares in the last quarter. National Asset Management Inc. acquired a new position in Crispr Therapeutics in the 2nd quarter valued at about $362,000. Finally, Wells Fargo & Company MN grew its position in Crispr Therapeutics by 23.9% in the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after acquiring an additional 116,540 shares in the last quarter. 49.82% of the stock is owned by institutional investors.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: Forex
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.